Full Press Release Details
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q2 2026 Earnings Release
LCTX Neutral Sentiment
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Key Takeaway: Lineage Cell Therapeutics has released its financial results for the second quarter of 2026. The report includes key updates on the company's business activities. Further details on earnings and operational performance were shared in the release.
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~17 mo
Low dilution risk
Lead asset
GRNVAC1
Phase 2 · Acute Myelogenous Leukemia